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Reason for performing the study: Cardiac output does not always increase with dobutamine 
administration in anaesthetised horses and information on peripheral perfusion is lacking. 
Objective: Determine the effect of intravenous dobutamine infusion with and without a 
concurrent 20 mL kg-1 bodyweight bolus of crystalloid fluids on the cardiovascular function 
of hypotensive, isoflurane-anaesthetised horses premedicated with acepromazine. 
Study design: Prospective, randomised, crossover experimental design.  
Methods: Six horses aged 5-13 years, weighing 464-578 kg were premedicated with 
acepromazine 0.02 mg kg-1, then sedated with xylazine 0.8 mg kg-1 intravenously. 
Anaesthesia was induced with ketamine 2.2 mg kg-1 and diazepam 0.08 mg kg-1 intravenously 
and maintained in lateral recumbency with isoflurane, adjusted to achieve a target mean 
arterial pressure (MAP) (60mmHg+/-5%) 60 minutes post-induction of anaesthesia (T0).  One 
of two randomly allocated treatments was then given.  In treatment D, dobutamine was 
initially infused at 0.5 µg kg-1 min-1 and adjusted to achieve a target MAP (80 mmHg +/- 5%) 
within 30 minutes of infusion initiation.  In treatment D+F dobutamine was administered as 
described for treatment D, with 20 mL kg-1 bodyweight Hartmann’s solution infused 
intravenously over 20 minutes.  Cardiac index (CI), haemoglobin concentration ([Hb]), 
arterial oxygen content (CaO2), oxygen delivery index (DO2I) and bilateral femoral arterial 
blood flow (FBF) were recorded at T0, 30 minutes following dobutamine initiation (T1) and 
15 minutes following dobutamine cessation (T2).  Data were analysed using a mixed effect 
linear model (P<0.05 considered significant) and presented as mean +/- 95% confidence 
intervals.   
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Results: During treatment D, a significant increase was observed in DO2I, CaO2 and [Hb] 
between T0 and T1. While CaO2 and [Hb] remained significantly higher at T2 compared to 
T0, DO2I at T2 was not significantly different from T0.  During treatment D+F a significant 
increase was observed in FBF between T0 and T1. However FBF at T2 was not significantly 
different from T0. A significant difference between treatments was recorded at T1 for [Hb] 
and CaO2 and at T2 for [Hb].  There was no change in CI during either treatment. 
Conclusion: Administration of dobutamine alone significantly increased DO2I while co-
administration of dobutamine and fluids did not. In contrast co-administration of crystalloid 





I would really like to take this opportunity to sincerely thank my supervisor Dr Anthea Raisis 
for her help and guidance with this study and also to Dr Cristy Secombe and Dr Guy Lester.   
I would like to thank Professor Giselle Hosgood for her help with the statistical interpretation 
of the data in this study. 
I would also like to thank the equine department who had a big role in managing the study 
horses during the data collection period, in particular I would like to mention Ginny Philips 
and Randol Prowse, thank you. 
To all those in the anaesthesia department for providing us with the time off clinics necessary 
to perform the study, thank you.   
Finally to the horses involved in this study, without whom this study would not have been 






BP Blood pressure 
BSA Body surface area 
BW Body weight 
CaO2 Arterial oxygen content 
CI Cardiac index 
DA Dopamine 
DAP Diastolic arterial pressure 
DO2I Oxygen delivery index 
ECG Electrocardiogram 
ET Left ventricular ejection time 
ETCO2 End tidal CO2 
ETiso % End tidal isoflurane percentage 
FBF Femoral blood flow 
[Hb] Haemoglobin concentration 
HR Heart rate 
LDF Laser doppler flowmetry 
LPRF Low pulse repetition frequency 
LRS Lactated ringers solution 
MAP Mean arterial pressure 
Na+ Sodium 
PaCO2 Arterial blood partial pressure of carbon dioxide 
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PaO2 Arterial blood partial arterial pressure of oxygen 
PCV Packed cell volume 
Qt Cardiac output 
RR Respiratory rate 
SaO2 Haemoglobin oxygen saturation 
SAP Systolic arterial pressure 
SI Stroke index 
SV Stroke volume 
SVR Systemic vascular resistance 
TAV Time averaged mean velocity 
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1 Literature Review 
1.1 Perioperative mortality in horses 
The perioperative death rate reported in healthy horses varies, with rates of 0.09%, 0.63%, 
0.68 % and 0.9% being recorded in different studies (Bidwell 2007, Johnston et al 2002, Mee 
et al 1998a, Young and Taylor 1993). Much higher rates 4.3 and 11.7% are reported for 
horses undergoing emergency abdominal surgery (Mee et al 1998b, Johnston et al 2002) 
These figures are higher than the anaesthetic related death rates (ASA 1-5) in dogs, cats and 
humans of 0.17%, 0.24% (Brodbelt et al 2008), and 0.0018% (Gibbs 2012) respectively.  The 
relatively high mortality rate associated with anaesthesia in horses has resulted in numerous 
studies investigating causal factors and appropriate methods for preventing/treating these 
causes.  
1.2 Cause of perioperative mortality.  
The majority of anaesthetic related deaths in horses can be attributed to abnormalities in 
cardiovascular function, including cardiac arrest (33%) and myopathies (7%) (Johnston et al 
2002).  
1.2.1 Postanaesthetic myopathy and equine perioperative mortality 
Post anaesthetic myopathy contributes to morbidity and mortality in horses in a variety of 
ways. Firstly, Johnston et al 2002 stated that horses in pain on recovery are at increased risk 
of fracture during recovery.  Myopathy is a painful condition and this painful stimulus can 
lead to repeated premature attempts to stand in recovery at a time when the horse lacks the co-
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ordination to do so.. Limb fracture can occur during these repeated uncoordinated attempts to 
stand, often necessitating euthanasia.  Furthermore, muscle pain can prevent the horse from 
standing and result in progressive muscle damage often with poor response to analgesia, 
ultimately requiring euthanasia.  In addition, the extensive muscle damage results in, 
myoglobinemia and myoglobinuria, which may precipitate acute renal failure as myoglobin is 
nephrotoxic in high concentrations. Finally horses with severe myopathy that survive the 
acute phase may suffer loss of muscle group function, as a result of neurogenic muscle 
atrophy +/- muscle fibrosis and contracture which result in permanent functional impairment 
(Hennig and Court 1991).  
Aetiology of post-anaesthetic myopathy 
Post-anaesthetic myopathy is caused by muscle ischaemia that develops during anaesthesia 
(Trim and Mason 1973, Lindsay 1980) and/or subsequent reperfusion injury, resulting in 
muscle necrosis.  Factors that contribute to muscle ischaemia include hypoxaemia, poor body 
positioning, prolonged duration of anaesthesia, and poor padding on the surgical table. 
However one of the most important factors contributing to ischaemia is decreased vascular 
perfusion pressure due to decreased arterial +/- increased venous pressure and/or increased 
intramuscular compartmental pressure (Lindsay et al 1980).  
The role of hypotension in the development of post-anaesthetic myopathy 
Hypotension represents the most common adverse event that occurs during inhalational 
anaesthesia in horses (Wagner 2009).  Several studies have clearly demonstrated a 
relationship between decreased mean arterial blood pressure (MAP) and the development of 
post-anaesthetic myopathy.  In one study seven mechanically ventilated halothane 
anaesthetised horses were subjected to two separate anaesthetics: in one, horses were exposed 
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to a three hour period of normotension (MAP 80-90 mmHg); and in the other, a three-hour 
period of hypotension (MAP 50-55 mmHg), induced using high inspired halothane 
concentrations.  All hypotensive horses developed post anaesthetic myopathy, with two 
horses requiring euthanasia. The remaining four horses recovered over the ensuing 12-72 
hours.  Only one horse in the normotensive treatment developed a transient myopathy, which 
resolved within 24 hours (Lindsay et al 1989).  These findings were confirmed in a 
subsequent study of six laterally recumbent, mechanically ventilated halothane anaesthetised 
horses, subjected to two anaesthetic protocols (Grandy et al 1987).  During one anaesthetic, 
horses experienced a 3.5-hour period of normotension (85-95 mmHg) and during the other a 
3.5-hour period of hypotension (55-65 mmHg).  As with the previous study, hypotension was 
achieved by increasing the inspired concentration of halothane.  All six horses in the 
hypotensive treatment developed post anaesthetic myopathy with three horses requiring 
euthanasia.   
Interestingly the affected limb in four of the six horses was the non-dependent limb. A 
subsequent study by Raisis et al (2005) in laterally recumbent anaesthetized horses reported 
that blood flow in the non-dependent limb was lower than the dependent limb.  The lower 
blood flow in the non-dependent limb could represent a gravitational lowering of hydrostatic 
pressure within these vessels due to position above the heart level and may explain why 
myopathy was observed more commonly in the non-dependent limb in the studies by Grandy 
et al (1987). 
The importance of hypotension in the development of post anaesthetic myopathy in a clinical 
setting has also been demonstrated. A retrospective clinical study by Young and Taylor 1993 
was performed in 1,314 halothane-anaesthetised horses.  Horses were premedicated with 
acepromazine and induced with varying techniques.  Retrospectively horses were divided into 
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two groups, the first group (n=575) included horses with hypotension (MAP <70 mmHg) that 
were not treated and the second group (n=739) horses with hypotension that were treated with 
fluid and dobutamine administration.  The first group had a significantly lower blood pressure 
than the second group. In both groups, seven horses developed post anaesthetic myopathy, 
(1.2% of hypotensive horses and 0.95% of normotensive horses).  In the first group, 5 of the 7 
cases were fatal, while in the second (normotensive) group all horses survived.  This study 
demonstrated that although the rate of occurrence of post anaesthetic myopathy was similar 
between both groups there was a marked decrease in the severity of the condition, if the 
hypotension was treated.  
1.3 Pathophysiology of hypotension 
The role of hypotension in post anaesthetic myopathy highlights the importance of the rapid 
recognition and management of low arterial blood pressure (BP) (hypotension) in 
anaesthetized horses in order to reduce the risk of morbidity and mortality in the peri-
anaesthetic period. This has lead to extensive research into methods for correcting 
hypotension in anaesthetized horses. However to select appropriate treatment it is important to 
understand the factors influencing BP and how these are altered during anaesthesia. 
1.3.1 Normal regulation of blood pressure 
Blood pressure is defined as the force exerted by blood within a vessel, on the walls of that 
vessel (Grosenbaugh and Muir 1998a).  Blood pressure is a product of cardiac output (Qt) and 
systemic vascular resistance (SVR).  Cardiac output is the product of heart rate (HR) and 
stroke volume (SV), which is determined by preload, cardiac contractility and afterload.  
Preload, or end-diastolic volume, is influenced by venous return and compliance of the right 
atrium, while afterload is in part influenced by SVR, which provides resistance to forward 
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ejection of blood from the heart.  Systemic vascular resistance is influenced by changes in 
peripheral vascular tone. Vascular smooth muscle relaxation will decrease SVR while 
vascular smooth muscle constriction will increase SVR.  
Increased preload and cardiac contractility and decreased afterload increase Qt, while 
decreased preload, cardiac contractility and increased afterload will decrease Qt.   
1.3.2 Relationship between arterial blood pressure and tissue perfusion 
The relationship between BP and tissue perfusion is complicated. Typically increases in Qt 
and SVR will increase ABP and thus increase tissue perfusion by increasing perfusion 
pressure. However increases in SVR can also decrease tissue perfusion due to accompanying 
vasoconstriction.  Furthermore, the increased SVR causes an increase in afterload, which can 
decrease Qt.  This is important to understand when selecting drugs that correct low BP.  
1.3.3 Effect of anaesthesia on blood pressure  
There are a number of factors, which can contribute to the generation of hypotension during 
equine anaesthesia, including the effects of sedative and anaesthetic drugs on the 
cardiovascular system, and confounding effects of horse positioning and the mode of 
ventilation used during anaesthesia.  The following review will focus on the effects of 
sedative and anaesthetic drugs as this is more relevant to the studies outlined in this thesis.  
Anaesthetic drugs 
Of the drugs commonly used for sedation and anaesthesia in horses, those most commonly 
associated with hypotension are acepromazine, alpha2 adrenergic agonists and the inhalational 




Acepromazine (ACP) is routinely used as a premedicant in horses as it is associated with 
inhibition of conditioned avoidance behaviour (Tranquilli et al 2007), and decreased 
anaesthetic requirements for horses during general anaesthesia (Doherty et al 1997).  There is 
also evidence to suggest that ACP may decrease the frequency of anaesthetic related deaths 
(Johnston et al 2002).  
Acepromazine is an alpha-adrenergic antagonist (Tranquilli et al 2007), which causes vascular 
smooth muscle relaxation. The associated vasodilation results in decreased SVR and blood 
pressure and as a result decreased preload (Harvey and Ettinger 2007), which persists for at 
least two hours (Pequito et al 2013). 
Alpha-2 agonists 
Alpha-2 adrenoceptor agonist drugs including xylazine, romifidine, detomidine and 
medetomidine are commonly used in equine anaesthetic regimes to provide sedation prior to 
induction of anaesthesia. Alpha-2 agonists are classically associated with a biphasic 
cardiovascular response characterised by an initial increase in BP which is accompanied by 
decreased HR and cardiac index (CI), followed by a decrease in BP and then gradual return of 
HR and CI to baseline.  Alpha-2 adrenergic agonists can contribute to the development of 
hypotension, during the second phase of this response.  Duration of these effects varies with 
different alpha 2 agonists. Significant changes in cardiac function are dissipated by 60 
minutes following single dose of xylazine (Yamashita et al 2000), while cardiovascular 
changes associated with romifidine and detomidine last up to 2 hours (Freeman et al 2002, 





Isoflurane and halothane produce dose dependent changes in cardiovascular function (Steffey 
and Howland 1980).  Although both agents can produce similar decreases in BP (Raisis et al 
2005, Grosenbaugh and Muir 1998b), the mechanism by which these agents affect BP differs. 
The decrease in BP associated with halothane is predominantly caused by a decrease in Qt, 
secondary to a decrease in myocardial contractility and associated decrease in stroke volume.  
During halothane anaesthesia in spontaneously breathing horses, Qt decreases up to 40% 
(Hillidge and Lees 1975).  In contrast, the decrease in BP during isoflurane anaesthesia is 
predominantly associated with vasodilation and decreased SVR, with minimal decreases in Qt 
observed between conscious and spontaneously breathing anaesthetised horses, induced and 
maintained with isoflurane (Steffey et al 1987).  Greater cardiac function is observed during 
equipotent isoflurane anaesthesia compared to halothane anaesthesia, although the difference 
is diminished during controlled ventilation (Steffey and Howland 1980, Mizuno et al 1994, 
Raisis et al 2000b, Blissitt et al 2008).  
1.3.4 Management of hypotension in the horse 
There are several methods used to treat hypotension in anaesthetised patients including 
administration of intravenous fluids and pharmacological agents. The latter are the most 
commonly used in anaesthetised horses. 
Pharmacological agents 
Pharmacological agents used to treat hypotension mediate increases in blood pressure by 
increasing SVR (vasopressor drugs), increasing cardiac contractility (inotropic drugs) or both. 
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Agents that have been investigated in horses include phenylephrine, isoproterenol, ephedrine, 
dopamine, dobutamine and dopexamine. 
Phenylephrine  
Phenylephrine is an alpha-1 adrenergic agonist that causes vasoconstriction in most vascular 
beds including renal, splanchnic, cutaneous, and limbs, although coronary artery blood flow is 
maintained (Crystal et al 1991).  In halothane-anaesthetised horses, phenylephrine 
administration is reported to cause an increase in BP and SVR, and a decrease in HR and Qt.  
Despite increases in MAP, peripheral perfusion was decreased in these studies (Lee et al 
1998, Raisis et al 2000c).  However, these studies were performed in normotensive horses and 
the effect of phenylephrine in hypotensive horses has not been determined. Furthermore, the 
effect of phenylephrine in isoflurane-anaesthetized horses has not been determined. Despite 
this lack of information, clinical use of phenylephrine is limited, this may be due to the 
concerns over vasoconstriction and reduced perfusion to vital organs such as kidneys, 
intestines and muscle. 
Dopamine 
Dopamine (DA) is a precursor of norepinephrine, but seems to have a dual effect on 
catecholamine release. A tonic inhibitory activity is mediated by DA2 receptors on 
sympathetic nerve endings and chromaffin cells.  A stimulatory action is mediated through 
DA1 receptors on chromaffin cells, increasing circulating levels of nor-epinephrine (Missale 
et al 1998).  Nor-epinephrine activation of post-synaptic DA1 receptors on vascular smooth 
muscle mediates vasodilation (Brodde 1982). The predominant receptor activated during 
dopamine administration, changes with the rate of drug administered.  At low infusion rates 
(1-5 µg kg-1 min-1) DA1 receptor activation, smooth muscle relaxation and increased renal 
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blood flow are seen, but BP is not affected. Intermediate infusion rates (5-10 µg kg-1 min-1) 
can increase BP predominantly by beta-1 receptor activation and associated positive inotropic 
and chronotropic effects.  At high infusion rates (>10 µg kg-1 min-1), increased BP is mediated 
by alpha-1 and -2 receptor mediated vasoconstriction.  Increased arrhythmogenicity is also 
observed at high infusion rates (Marsh 2010). 
Dopamine administration in halothane anaesthetized horses is reported to produce minimal 
changes in BP from baseline levels at low (2.5-5 µg kg-1 min-1) infusion rates, significant 
increases in BP and Qt at intermediate (10 µg kg-1 min-1) infusion rates and the development 
of severe muscle tremors and arrhythmias at high infusion rates >10-20 µg kg-1 min-1. 
(Swanson et al 1985, Lee et al 1998).   
Dopamine has not gained popularity in equine anaesthesia, due to its negative impact on BP at 
lower infusion rates, and the propensity for arrhythmogenicity at higher doses giving it a 
narrow clinically effective therapeutic range. 
Dopexamine 
Dopexamine hydrochloride is a novel synthetic catecholamine, structurally related to 
dopamine.  Dopexamine has marked intrinsic agonist activity at beta-2 adrenoceptors and less 
agonist activity at dopamine (DA1- and DA2) receptors and beta-1 adrenoceptors.  
Dopexamine also has an inhibitory action on the neuronal catecholamine uptake mechanisms.  
Overall dopexamine results in direct and indirect positive inotropism, arterial vasodilation and 
afterload reduction.  Selective renal vessel vasodilation and increased renal blood flow is also 
reported (Fitton and Benfield 1990, Lee et al 1998, Muir 1992a). 
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In halothane-anaesthetised horses dopexamine administration is reported to increase BP in 
association with increased HR and Qt, and decreased SVR (Young et al 1997, Muir 1992a, 
Muir 1992b). The first equine experimental study (Muir 1992a) was conducted in eight 
horses, premedicated with xylazine (0.25 mg kg-1) intravenously (IV), prior to induction of 
anaesthesia with guaifenesin (50 mg kg-1) and thiamylal (4 mg kg-1) IV.  Dopexamine was 
administered at 5, 10 and 15	  µg kg-1 min-1, for 10 minutes.  Blood pressure, HR and Qt, were 
significantly elevated and SVR significantly reduced from baseline levels during 
administration at 10 and 15 µg kg-1 min-1.  In this study the increase in Qt seen with 
dopexamine is believed to be the result of increased cardiac contractility and HR, and 
decreased SVR (Muir 1992a and b).   
Despite the favourable effects on cardiac output reported in this study, dopexamine is not 
routinely used in clinical practice. This is predominantly due to adverse effects of 
dopexamine, which include, profuse sweating during drug administration and excitement and 
violent shivering on recovery. Although not present in original studies (Muir 1992a and b), 
these adverse effects have been reported in horses anaesthetised with halothane, following 
sedation with alpha-2 agonists and induction of anaesthesia with ketamine (Young et a 1997, 
Lee et al 1998). 
Ephedrine 
Ephedrine is a non-catecholamine sympathomimetic amine, which works indirectly by 
stimulating the release of norepinephrine from sympathetic nerve endings (Weiner 1985) and 
directly by stimulating alpha and beta adrenoceptors (Schauvliege and Gasthuys 2013).  At 
low doses beta-1 and 2 adrenoceptor effects are equal in magnitude to alpha-1 effects, while 
at higher doses alpha-1 activity predominates (Daunt 1990).   
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Ephedrine administration (0.06 mg kg-1) in eight normotensive laterally recumbent halothane 
anaesthetized horses resulted in a significant increase in MAP associated with increased Qt 
and SV, while SVR and HR remained unchanged (Grandy et al 1989). Ephedrine 
administration at 0.2 mg kg-1 min-1 in seven hypotensive (MAP <60 mmHg) isoflurane 
anaesthetised horses also resulted in a significant increase in MAP that was associated with a 
significant increase in both Qt and SVR, with no change in HR. No arrhythmias were 
induced.   
The effectiveness of ephedrine is dependent on the activity of the sympathetic nervous 
system. When the sympathetic nervous system is maximally stimulated, ephedrine is less 
effective. In addition, the use of ephedrine can cause tachyphylaxis, which is an acute 
decrease in the response to a drug after its administration due to the depletion of 
norepinephrine stores within sympathetic neurons (Valette and Masse 1960).   
Ephedrine has been shown to be effective at correcting hypotension during equine 
anaesthesia. However as its effects are caused in part by release of nor-adrenaline from nerve 
endings  its use in hypotensive patients that may have altered sympathetic nervous system 
function is not known. In addition, its relatively long duration of action makes the titration of 
this drug to effect difficult.  
Dobutamine 
Dobutamine is currently the most commonly investigated agent for the management of 
hypotension in anaesthetized horses. Dobutamine is a synthetic catecholamine, derived from 
isoproterenol (Tuttle and Mills 1975).  Dobutamine is commercially available as a racemic 
mixture.  The negative enantiomer is a relatively strong alpha adrenergic and weaker beta-1 
and beta-2 adrenergic agonist, while the positive enantiomer is a strong beta-1 and beta-2 
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adrenoceptor agonist with only mild alpha	 adrenergic activity (Ruffolo and Yaden 1983).  
The racemic mixture of dobutamine has a strong affinity for both beta-1 and beta-2 
adrenoceptors, which it binds to at a 3:1 ratio.  With its cardiac beta-1 stimulatory effects, 
dobutamine is an effective inotrope, with weaker chronotropic activity.  The effect of 
dobutamine on the vascular system is variable, related in part to the dose of dobutamine 
administered, and includes alpha-1	   mediated vasoconstriction and beta-2 mediated 
vasodilation.  The net vascular effect is often mild vasodilation at lower doses, with 
vasoconstriction dominating at higher infusion rates (Overgaard and Džavík 2008).   
Initial experimental studies in halothane anaesthetized horses demonstrated that dobutamine 
administered at 3, 5 and 10 µg kg-1 min-1 increased BP due to increased myocardial 
contractility and Qt (Swanson et al 1985).  Donaldson et al (1988) confirmed the effectiveness 
of dobutamine in a clinical setting, with 79 % (n=200) of hypotensive (MAP <70 mmHg) 
halothane anaesthetised horses responding to dobutamine (1.5-3.2 µg kg-1 min-1) with a ≥10 
mmHg increase in BP within 10 minutes of onset of the infusion. Unfortunately Qt was not 
measured in this study.  
A number of subsequent experimental studies in halothane-anaesthetised horses demonstrated 
a significant increase in BP with dobutamine infusions of 0.5-10 µg kg-1 min-1 (Raisis et al 
2000a, Dyson and Pascoe 1990, Young et al 1998, Lee et al 1998).  However, only some of 
these studies demonstrated a concurrent increase in Qt with dobutamine infusions of 2.5-10 
µg kg-1 min-1 (Dyson and Pascoe 1990, Young et al 1998, Lee et al 1998).  In contrast to 
original work by Swanson et al 1985, the increases in Qt were attributed to concurrent 
increases in HR (Young et al 1998) or increases in HR and SV (Dyson and Pascoe 1990, Lee 
et al 1998).  An increase in Qt was not observed in the study performed by Raisis et al 
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(2000a).  The results of these studies demonstrate that in halothane anaesthetized horses the 
cardiovascular effects of dobutamine are variable.   
Variable effects have also been reported with the administration of dobutamine in isoflurane-
anaesthetised horses. Mizuno et al (1994) demonstrated a significant increase in MAP 
associated with increased Qt, attributed to increased SV, when dobutamine (0.5-2	  µg kg-1 min-
1, 0.86 +/- 0.3 (mean+/-SD)) was administered to achieve a target MAP of 70 mmHg.  In two 
subsequent studies, dobutamine administered at a mean (SD) dose of 0.9 (1.0) µg kg-1 min-1 
(Durongphongtorn et al 2006) and 1.1 (0.6) µg kg-1 min-1 (de Vries et al 2009) achieved a 
target MAP of 70-80 mmHg, but failed to cause a significant increase in Qt until after the 
onset of surgical stimulation. Furthermore the increases in Qt seen in these two studies were 
associated with significant increases in HR.  An increase in BP without an increase in Qt 
suggests that SVR is increased. If this is the case the increase in BP may not necessarily be 
associated with increased tissue perfusion.  
The effect of dobutamine on peripheral blood flow 
Information regarding the effects of dobutamine on peripheral blood flow is limited to a small 
number of studies in halothane-anaesthetised horses.  In one study by Raisis et al (2000a), the 
administration of dobutamine (0.5 µg kg-1 min-1 for 30 minutes) in laterally recumbent 
halothane anaesthetised horses was associated with a significant increase in bilateral femoral 
blood flow, despite no significant increase in CI.  This study failed to show a change in hind 
limb microvascular perfusion, measured using laser Doppler flowmetry (LDF) (Raisis et al 
2000a).  In contrast in a study by Lee et al 1998, dobutamine administration at 2.5, 5 and 10 
µg kg-1 min-1 in eight laterally recumbent halothane anaesthetised ponies produced a 
significant increase in Qt and bilateral forelimb microvascular flow.    
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The variable changes in the microvasular flow between studies may represent the limitations 
of the LDF technique used to measure intramuscular blood flow, the differences in the size of 
horses used and the associated increases in intracompartmental pressure, the site of 
measurement (forelimb versus hind limb) or the different infusion rates of dobutamine. 
To date there are no studies investigating the effect of dobutamine administration on 
peripheral blood flow in isoflurane-anaesthetized horses.  
Possible reasons for inconsistent cardiovascular effects of dobutamine  
The variable response to dobutamine in halothane and isoflurane anaesthetized horses may 
reflect an interaction between dobutamine and the different anaesthetic protocols used, 
including acepromazine (de Vries et al 2009, Dyson and Pascoe 1990), guaiphenesin and 
thiopentone (Dyson and Pascoe 1990); xylazine and ketamine (Mizuno et al 1994, Lee et al 
1998), romifidine and ketamine (Raisis et al 200a, Young et al 1998, Durongphongtorn et al 
2006), detomidine and ketamine (de Vries et al 2009).  
There are limited studies assessing the interaction between dobutamine and other anaesthetic 
agents in horses.  Studies in dogs, suggest that ACP can alter the effectiveness of vasoactive 
drugs such as phenylephrine and dopamine on cardiovascular function in halothane and 
isoflurane anaesthetised dogs (Ludders et al 1983, Monteiro et al 2007).  Premedication with 
or without acepromazine (0.025 - 0.05 µg kg-1) did not alter the effects of dobutamine on 
increasing MAP in six isoflurane anaesthetised horses (Monteiro et al 2011), however 
unfortunately Qt was not measured in this study.  A recent experimental study in isoflurane 
anaesthetized horses, failed to demonstrate differences in effect of dobutamine on Qt in 
unpremedicated horses and horses premedicated with acepromazine (Schier et al 2014). 
Page 25 
 
Interestingly, no significant increase in CI was observed during either treatment, suggesting 
some other factor was contributing to the variable cardiac response to dobutamine.     
There is also evidence that alpha-2 agonists can alter the effects of vasoactive agents. The 
administration of the α2-agonist clonidine, in people, has been shown to inhibit the 
chronotropic effects of dobutamine (Zimpfer et al 1982).  However, premedication with or 
without xylazine in 11 halothane-anaesthetised horses, was not found to alter the effect of 
dobutamine on cardiac function (McMurphy et al 2003). The effect of the other alpha-2 
agonists has not been determined at this time.  
It is also possible that the inhalational anaesthetic agent used could be contributing to the 
variable effects seen.  Isoflurane and acepromazine are both known to produce vasodilation, 
which causes hypotension and decreased preload (Harvey and Ettinger 2007).  If significant, 
the reduced preload could alter the ability of the heart to increase stroke volume in response to 
dobutamine administration (Robertson 2010).   
Fluid Administration in the treatment of hypotension 
If preload is reduced in horses receiving isoflurane and/or acepromazine, it is also possible 
that concurrent administration of fluids may improve the effects of dobutamine on Qt by 
improving preload.   
To date the use of fluid therapy in anaesthetised horses has received little attention.  In 
contrast fluid therapy has been studied extensively in the treatment of hypotension, 
hypovolaemia and low Qt in human medicine.  The three main fluid types that have been 
studied are synthetic colloids and isotonic and hypertonic crystalloid fluids.  There are 
minimal reports on the use of synthetic colloids in anaesthetized horses. Considering the 
recent reports of increased mortality (Perner et al 2012) associated with the use of hydroxyl-
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ethyl starch in septic human patients, and the cost of synthetic colloid in a large animal such 
as the horse, routine use of colloids may not be advisable. The use of hypertonic saline in 
horses as a means of fluid resuscitation is controversial owing to concerns of intracellular 
fluid deficits (Fielding and Magdesian 2011). Thus the remaining discussion will focus on use 
of isotonic crystalloid fluid administration, as this is relevant to the studies outlined in this 
thesis.  
Benefits of crystalloid fluid administration 
There is evidence to support the usefulness of crystalloid fluids for management of 
hypotension associated with regional and general anaesthesia in human patients. 
Research regarding optimal fluid type and time of administration in patients scheduled for 
conscious caesarean delivery under epidural anaesthesia, found a significant (16%) decrease 
in the incidence of hypotension when patients received a 20 mL kg-1 crystalloid bolus prior to 
epidural injection compared to those that did not (Rout et al 1993).  Further decreases in 
hypotension were shown when the 20 mL kg-1 crystalloid bolus was started at the time of 
(coload), rather than prior to epidural injection (Dyer et al 2004).   
There is minimal literature available on the use of fluids to treat cardiovascular compromise 
in horses. In an experimental study, six horses were randomly allocated to either 
acepromazine premedication 0.05mg kg-1 IV or acepromazine 0.05 mg kg-1 IV premedication 
followed immediately by a 20 mL kg-1 Lactated Ringer’s solution (LRS) infusion (Dyson and 
Pascoe 1990).  Anaesthesia was induced with guaifenesin (100mg kg-1) and thiamylal (5 mg 
kg-1) IV and maintained with halothane for 45 minutes. Mean arterial pressure and CI were 




The effects of two different volumes of crystalloid have also been studied experimentally in 
12 endotoxaemic halothane anaesthetized horses.  Horses were randomly allocated to receive 
either, a 15 mL kg-1 or 60 mL kg-1 bwt crystalloid bolus, administered over 30 minutes during 
anaesthesia.  The small volume group achieved a significant increase in Qt for 60 minutes 
following infusion completion, 30 minutes longer than that seen in the large volume group.  
There was no significant difference in MAP or SVR between groups (Pantaleon et al 2006).  
This result was unexpected but interesting and supports the fact that hypotension in horses can 
be successfully managed with small volumes of fluid given rapidly.  
Combination of crystalloids and pharmaceutical agents for treatment of hypotension 
The co-administration of fluids and pharmacological agents for the management of 
hypotension has not been studied in anaesthetised horses, but is supported by studies in other 
species. In the human literature, the combined use of fluid therapy and pharmacological 
agents has been shown to be more effective at treating hypotension than the use of 
pharmacological agents alone.   In conscious humans receiving epidural anaesthesia, the rate 
and total dose of phenylephrine required to maintain normotension, were lower when 
phenylephrine was co-administered with a crystalloid (2L) infusion (Ngan et al 2005).  Dogs 
treated with rapid crystalloid fluid administration (volume equating to three times the volume 
of bleeding) and vasopressin, have demonstrated significantly improved cardiac index, SAP, 
DO2I and oxygen consumption index, compared to treatment with vasopressin alone (Yoo et 
al 2007).   
The results of these studies indicate that fluid administration in combination with vasoactive 
agent administration may be preferable to either treatment in isolation when treating 
hypotension.  Similar studies of fluid administration and inotropes have not been performed in 
any species. However it is reasonable to expect that in the presence of reduced preload, as 
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expected with use of vasodilatory drugs such as acepromazine in combination with isoflurane, 
fluid therapy should improve the ability of the heart to respond to inotropes. Based on these 
findings, and the inconsistent effects of dobutamine currently reported in anaesthetized 
horses, it is possible that the combined use of dobutamine and a rapid crystalloid infusion may 
produce a more consistent and sustained increase in Qt that is associated with an increase in 
SV rather than HR.  It is also possible that the co-administration of fluids will lower the rate 
of dobutamine required to achieve target BP.    
1.4 Summary 
Hypotension is a common problem in anaesthetised horses for which dobutamine is often the 
primary treatment.  Dobutamine is effective at increasing BP, but does not consistently result 
in increases in Qt.  An increase in BP without increase in Qt suggests increases in SVR, 
which could be detrimental to peripheral perfusion.  The exact reason Qt does not always 
increase during dobutamine administration is not known.  However if lack of improvement in 
Qt during dobutamine administration is associated with decreased preload due to 
administration of anaesthetic agents that cause vasodilation, combined use of dobutamine and 
fluid therapy in hypotensive isoflurane anaesthetized horses may lead to more consistent 
increases in Qt and better peripheral perfusion.  
Page 29 
 
2 Methods and materials 
2.1 Aim and hypothesis of this study 
The first aim was to determine the effect of a dobutamine infusion with and without a 
concurrent 20 mL kg-1 bwt bolus of crystalloid fluids on cardiovascular function in isoflurane 
anaesthetised horses.   
It was hypothesized that the combination of dobutamine infusion and crystalloid fluid 
administration would increase CI, DO2I and FBF above baseline, whereas dobutamine alone 
would not. 
The second aim was to determine the effect of a dobutamine infusion with and without a 
concurrent 20 mL kg-1 bwt bolus of crystalloid fluids on cardiovascular function, 15 minutes 
after treatment was stopped. 
It was hypothesized that following administration of dobutamine and fluids, DO2I, FBF and 
BP would remain increased compared to baseline, 15 minutes after stopping treatment, and 
that following administration of dobutamine alone, DO2I, FBF and BP would remain 
unchanged compared to baseline 15 minutes after stopping treatment.  
The third aim was to determine the dose rate of dobutamine required to achieve the target 
MAP when used alone and when combined with crystalloid fluids. 
It was hypothesized that the dose rate of dobutamine required to achieve the target MAP 
would be lower when horses received dobutamine and crystalloid fluids when compared to 
dobutamine alone.  
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2.2 Materials and methods 
2.2.1 Animals 
Four standardbred and two thoroughbred geldings aged 5-13 years, weighing 464-578 kg, 
were included in this study.  Use of the horses in this study was approved by the Animal 
Ethics Committee of Murdoch University (AEC Permit No: 2526/12).   
Physical examination, echocardiography and electrocardiography were performed prior to 
enrolment of horses in the study to ensure horses were free of overt heart disease.  Clinical 
examination of the horses was again performed 24 hours prior to anaesthesia and on the 
morning of anaesthesia.  Measurement of packed cell volume (PCV) and total solids (TS) was 
also performed to ensure normal hydration.  Venous blood was collected from the left jugular 
vein using a heparinised syringe (Radiometer Medical ApS Akandevej 21, 2700 Bronshoj, 
Denmark). Samples were aspirated into microhaematocrit tubes, and then centrifuged within 
15 minutes of collection (Centurion Scientific C2 series, The Old Stables, Churchfarm, 
Chester, West Sussex, PO18 9JL).  Packed cell volume was measured using a 
microhaematocrit reader (Clements, Cat no: 96226, Ringwood, Victoria, Australia) and TS 
were measured using a refractometer (Reichert Vet 360 Total Solids Refractometer, Reichert 
Analytical Instruments, Reichert, 3362 Walden Ave, Depew, NY 14043, USA).  Food and 
water were withheld from the time of premedication. 
Each horse was anaesthetised twice with a minimum of three weeks between anaesthetics.  
Using a crossover design, horses were randomly allocated using a random number generator 
computer program (http://www.randomizer.org/form.htm) to one of two treatments (treatment 
D or treatment D+F) for the first trial.  The horses then received the alternative treatment 
during the second anaesthetic.  Treatment D consisted of administration of a dobutamine 
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infusion alone and treatment D+F consisted of concurrent administration of a dobutamine 
infusion and Hartmann’s solution.  No other fluids were administered during anaesthesia.   
The anaesthetist was not blinded to the treatment given. 
Catheterization of the jugular vein was performed prior to premedication in all horses.  Horses 
receiving treatment D had a 14g, 5” single lumen catheter (Angiocath, Becton Dickinson, 
Infusion Therapy Systems Inc.  9450 S State, Sandy, Utah 84070) placed in the left jugular.  
Horses receiving treatment D+F, had a 12 g, 5” single lumen catheter placed in the left jugular 
and 14 gauge catheter placed in the right jugular.   
2.2.2 Anaesthesia 
All horses were premedicated with 0.02 mg kg-1 ACP administered IV (Delvet B4 26 Powers 
Road, Seven Hills NSW 2147).  Thirty minutes after administration of ACP horses were 
sedated with 0.8 mg kg-1 xylazine (Troy Laboratories PTY. Ltd, Glendenning NSW 2761 
Australia) IV.  Anaesthesia was induced five minutes later with 2.2 mg kg-1 ketamine 
(Ketamil, llium Veterinary Products, Troy Laboratories Pty Ltd, NSW, Australia) and 0.08 
mg kg-1 diazepam (Troy Laboratories PTY. Limited, Glendenning, NSW 2761, Australia) 
administered as a single IV injection over 15 seconds.  Orotracheal intubation was performed 
using a 26 mm internal diameter cuffed endotracheal tube (VCS Distributed by: Veterinary 
Companies of Australia PTY LTD, NSW, Australia). Horses were then hoisted and 
positioned in right lateral recumbency on a padded surgical table.  Anaesthesia was 
maintained with isoflurane (VCS Distributed by: Veterinary Companies of Australia PTY 
LTD, NSW, Australia) delivered in up to 98 % oxygen via a large animal circle system.  
After stabilization and instrumentation (see below), the administered dose of isoflurane was 
adjusted to achieve a target MAP of 60 mmHg +/- 5 %.  Mechanical ventilation was 
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performed using a large animal anaesthetic machine and ventilator (Surgivet LDS 3000, 
Smiths Medical PM Inc, Waukesha, Wisconsin, USA) throughout anaesthesia to maintain 
arterial carbon dioxide tension (PaCO2) between 45-55 mmHg (6.0-7.3kPa). Routine 
monitoring including electrocardiography (ECG), pulse oximetry, temperature and invasive 
BP was continuously displayed and recorded using a multivariable monitor (Advisor Vital 
Signs surgivet Monitor V9212AR Smiths Medical PM Inc, Waukesha, 53186, USA).  End 
tidal CO2 tension (PETCO2), and inspired and expired isoflurane percentage were monitored 
throughout anaesthesia with a Capnomac Ultima (Datex, Devision of Instrumentation Corp, 
Helsinki, Finland), which was calibrated daily during the experimental period.   
2.2.3 Instrumentation 
A 20g 1.16” arterial catheter (BD Insyte, Becton Dickinson Infusion Therapy Systems Inc. 
Sandy, Utah 84070, USA) was placed in the left transverse facial artery for measurement of 
BP, collection of blood for blood gas analysis and measurement of lithium chloride for 
determination of Qt. The catheter was connected via a fluid filled pressure transducer, 
(DTXplus disposable pressure transducer, Argon Critical Care Systems Singapore Pty. Ltd 
198 Yishun Avenue 7, Singapore 768926) to the multivariable monitor. The pressure 
transducer was positioned at the level of the sternum and zeroed to atmospheric pressure prior 
to measurement acquisition.  
2.2.4 Treatment  
After instrumentation, the administered dose of isoflurane was adjusted to produce a target 
MAP of 60 mmHg +/- 5 % for at least 15 minutes prior to starting each treatment.  The end 
tidal isoflurane percentage (ETiso %) required to achieve this target MAP in each horse was 
recorded.  During treatment D and D+F, dobutamine was initially administered at 0.5 µg kg-1 
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min-1 and the dose was increased by 0.5 µg kg-1 min-1 every 5 minutes if required to achieve 
and maintain a target MAP of 80 mmHg +/- 5 % by 30 minutes after start of administration.  
The dobutamine dose required to achieve this target MAP in each horse was also recorded. 
With treatment D+F, 20 mL kg-1 Hartmann’s solution (Baxter Health Care PTY LTD, 1 
Baxter Drive, Old Toongabbie, NSW, Australia) was administered concurrently during the 
first 15-20 minutes of the dobutamine infusion. To avoid dilution of the dobutamine during 
Hartmann’s solution administration, the dobutamine infusion was administered via the right 
jugular and the Hartmann’s solution via the left jugular catheter.  
2.2.5 Data collection 
Data was recorded at the following sample times: T0 (60 minutes after induction of 
anaesthesia, after achieving a target MAP of 60 mmHg +/- 5 % and a stable ETiso % for ≥ 15 
minutes), T1 (at the end of the 30 minutes dobutamine infusion after achieving a target MAP 
of 80 mmHg +/- 5 %) and T2 (15 minutes post cessation of the dobutamine infusion).  
Data collected at each sample time included HR, SAP, DAP and MAP, Qt, bilateral FBF; 
PCV, TS, haemoglobin concentration [Hb], sodium concentration [Na+], arterial partial 
pressure of oxygen (PaO2) and arterial oxygen saturation (SaO2).  
Cardiac output was determined using the lithium dilution method according to previously 
published techniques (Linton et al 2000) using the LiDCOplus Hemodynamic Monitor 
(LiDCO Ltd, London, UK).  Prior to each Qt determination, the plasma [Na+] and [Hb] were 
measured using the Vet Scan Istat-1 (DRC-300V, Abbott Point of Care Inc, Union City, CA 
94587).  For each Qt measurement, 0.003 mmol kg-1 of lithium chloride was injected IV 
through the left jugular venous catheter.  Arterial blood was withdrawn from the left 
transverse facial arterial catheter by the LiDCO Flow Regulator, to produce the change in 
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voltage over time curve used to calculate Qt.  At each sample time, two Qt measurements 
were performed within five minutes.  The percentage difference between duplicate 
measurements was calculated as [(measurement 1- measurement 2)/measurement 1] x 100 
[Gunkel et al 2004, Kurita et al 1997]. 
Femoral arterial blood flow within the upper and lower hind limb was measured using 
transcutaneous Doppler ultrasonography according to previously published techniques (Raisis 
et al. 2000c).  The diameter of the vessel was obtained using a two dimensional longitudinal 
image of the vessel using ultrasound emitted at a frequency of 5MHz. The diameter of the 
vessel was calculated between two calipers positioned between the outer edge of the proximal 
wall and inner edge of the distal wall. An average of three measurements was performed for 
each vessel at each sample time.  After calculation of the diameter, the Doppler sample 
volume was positioned centrally within the vessel and set at maximum sample size of 
approximately 5 mm. The sample volume cursor was adjusted to align with the vessel walls 
and blood flow. The angle between the sample volume cursor and the ultrasound beam was 
measured and subsequently used to correct velocity calculations. Angle corrections of 
between 50° - 60° were obtained for each measurement. After the sample volume was 
correctly positioned, Doppler studies were performed in low pulse repetition frequency 
(LPRF) mode using ultrasound emitted at a frequency of 7.5 MHz.  When a good quality 
signal was obtained, at least five consecutive waveforms were selected and the time-averaged 
mean velocity (TAV) was then calculated automatically from the spectra.  All femoral arterial 
blood flow measurements were performed by a single experienced clinician. 
At the end of the anaesthetic all horses were recovered in a padded box and then returned to a 




2.2.6 Data analysis 
The measured indices of cardiovascular function were used to generate calculated indices of 
cardiovascular function using the formulae outlined in Table 2.1.  To allow comparison with 
current publications, calculated parameters were indexed using both Body surface area (BSA) 
(Chang et al 2012) and bodyweight. 
Statistical analysis 
Data sets were all considered continuous and tested for normality using the Shapiro-Wilk test 
with all data sets considered normally distributed based on failure to reject the null hypothesis 
of normality (P>0.05).  Normality of the models were confirmed based on QQ plots of the 
residuals.  Data are summarized as mean and 95% confidence interval.  Data was tested for a 
fixed effect of treatment and time using a mixed effect linear model that also included the 
random variance of horse across treatment.  Where there were significant interactions of 
treatment and time, post hoc a priori contrasts within and between treatments were made 
using Tukey’s adjustment for multiple comparisons.  An adjusted P value less than 0.05 was 
considered significant and is reported.  
The infused dose of dobutamine was compared across treatments using a paired t-test with P 
<0.05 considered significant.  Where there were no differences between treatments, sample 
size estimation for detecting the observed difference between treatments for paired parametric 
analysis at P <0.05 with a power of 0.8 was calculated.   
All analyses were performed by a statistician with standard computer software (SAS v 9.4 
SAS Institute Inc, Cary, North Carolina, USA). 
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Table 2.1: The formulae used in this study to generate calculated cardiovascular indices from measured cardiovascular variables. 
Indices Formulae 
BSA (m2)  10.5 × (body mass, in g)⅔ × 10-4       (Raisis et al 2005) 
CI (L m-2 minute-1) Qt (L minute-1) ÷BSA 
CI (L kg-1 minute-1) Qt (L minute-1) ÷BW 
SVI (mL m-2) CI ÷ HR (beats minute-1) × 1000 
CaO2 (mL L-1) [([Hb](g dL-1) × 1.34 × SaO2 (%)) + (0.0031 × PaO2 (mmHg))] × 10 
DO2I (mL minute-1 m-2) CI × CaO2 
UAFI and LAFI  (mL minute-1 m-2) (TAV (cm s-1) x cross-sectional area of vessel) ÷ BSA 
Cross sectional area of blood vessel (mm2) π × (vessel diameter ÷ 2)2 
BSA - Body Surface Area, CI - Cardiac Index, SVI - Stroke Volume Index, CaO2 - Arterial Oxygen Content, DO2I - Oxygen Delivery 
TAV – Time averaged mean velocity, Index, UL FBF - Upper Limb Femoral Arterial Blood Flow Index, LL FBF - Lower Limb 
Femoral Arterial Blood Flow Index 
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3  Results  
Complete data were obtained at T0 and T1 from all six horses. Measured and calculated 
cardiovascular data are summarised in Table 3.1.  Cardiovascular data from each horse is 
presented in Appendix 1 Table 1-4, 7-8. Measured and calculated indices of oxygenation and 
ventilation are summarised in Table 3.2.  Pulmonary data from each horse is presented in 
Appendix 1 Table 5, 6. Data was missing at T2 in two of the six horses receiving treatment 
D+F.  One horse receiving treatment D+F spontaneously moved 10 minutes after collection of 
data at T1, requiring IV thiopentone (Ilium Thiopentone, Troy Laboratories Ltd, Smithfield, 
NSW, Australia) administration to deepen the plane of anaesthesia. Blood gas results were not 
available at T2 for one horse receiving treatment D+F due to technical problems, and thus 
oxygen delivery could not be calculated. For T0 and T1 data from all 6 horses was used to 
calculate mean and confidence intervals. For T2, mean and confidence interval was calculated 
from the available data. Where data was missing the number of horses used to calculate the 
mean and confidence intervals are indicated in tables 3.1 and 3.2. Thirty-five paired Qt 
measurements were recorded during this study. The mean (95% confidence interval) for the 
difference between duplicate Qt measurements was 5.37 % (4.00-6.78 %).   
Ventilator peak inspiratory pressure 25-30 cmH2O (0.05-0.06 cmH2O/kg) (2.45-2.94 kPa), 
respiratory rate (RR) 6-8 breaths per minute and I:E ratio 1:2 were required to achieve an 
arterial carbon dioxide tension (PaCO2) between 45-55 mmHg (6.0-7.3 kPa) at baseline. The 
settings required in each horse were subsequently maintained throughout each anaesthetic and 
did not differ between treatments.   
The mean (95% confidence interval) end tidal isoflurane percentage required to achieve a 
target MAP of 60 mmHg +/- 5 % was 1.6% (1.4-1.8%) for horses receiving treatment D and 
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1.6% (1.4-1.9%) for horses receiving treatment D+F. The mean (95% confidence interval) 
dose of dobutamine required to achieve a target MAP of 80 mmHg +/- 5 % did not differ 
significantly between treatment D [1.0 (0.67-1.33) µg/kg/min] and D+F [0.75 (0.13–1.37) 
µg/kg/min] (P = 0.23).   
There was a significant interaction for treatment and time for DO2I (P=0.03). Post hoc 
comparisons within treatment D (Table 3.1) showed DO2I significantly increased between T0 
and T1 (P=0.008) and remained higher at T2 but was not significantly different to baseline (P 
= 0.55).  DO2I did not significantly differ within treatment D+F (T0 and T1 P=0.48; T1 and 
T2 P= 0.58; T0 and T2 P=1.0). There was no significant different for DO2I between 
treatments (P= 0.10). The estimated sample size required to detect a difference between 
treatments for DO2I was > 300.  There was no significant interaction for treatment and time 
for CI (P=0.992) or main effects (treatment P=0.870, time P=0.107) indicating no significant 
change in CI within or between treatments. There was a significant interaction of treatment 
and time for CaO2 (P=0.007) and [Hb] (P=0.002). Comparisons within treatment D showed 
CaO2 and [Hb] significantly increased from T0-T1 (P=0.0002, P=<0.0001, respectively) and 
remained significantly increased from baseline at T2 (P=0.0005, P=0.002, respectively).  
During Treatment D+F CaO2 and [Hb] did not significantly change.  The CaO2 and [Hb] were 
significantly higher for treatment D compared to D+F at T1 (P=0.0003, P=0.0001, 
respectively) and at T2 (P=0.047, P=0.013, respectively). There was a significant main effect 
of time for upper FBF (P=0.001) and treatment and time for lower FBF (treatment P=0.014, 
time P=0.002). Comparisons within treatment D+F showed FBF in the upper and the lower 
limbs significantly increased from T0-T1 (P=0.005, P=0.042, respectively). Comparisons 





Table 3.1. Mean (95 % confidence interval) measurements of cardiovascular function 
recorded in isoflurane-anaesthetised horses. Unless otherwise stated, data is presented for 6 
horses. T0, 60 minutes after induction of anaesthesia when MAP was 60 +/- 5 % mmHg for 
>15 minutes; T1, 30 minutes after onset of dobutamine administration after achieving a target 
of 80 (+/- 5%) mmHg; and T2, 15 minutes after stopping dobutamine (T2) in horses receiving 
dobutamine alone (D) or dobutamine and a 20 mL kg-1 bolus of Hartmann’s solution (D+F) 
intravenously. 
For variables with significant changes over time, means with the same superscript are not 
significantly different, while means with different superscript are significantly different. 
There were no differences between treatments at any time point.  Cardiovascular parameters 
with † were not tested. 
Parameter  Data collection point 




HR (bpm)† D 33.3 (28.9-37.7) 40.3 (24.9-55.7) 38.1 (27.0-49.1) 
 D+F 34.1 (30.1-37.8) 38.3 (24.0-42.6) 36.2 (31.8-40.5) (n=4) 
SAP (mmHg)† D 84.3 (76.6-92.0) 108.5 (97.2-119.7) 92.9 (88.1-97.8) 
 D+F 83.1 (78.7-87.4) 109.6 (101.0-118.3 97.2 (87.7-106.8) (n=5) 
DAP (mmHg)† D 50.4 (49.5-51.3) 64.6 (60.1-69.1) 59.8 (52.3-67.3) 
 D+F 47.5 (42.6-52.5) 66.5 (62.9-70.0) 63.9 (52.3-75.4) (n=5) 
MAP (mmHg) D 61.2 (58.5-64.0)a 78.7 (76.2-81.2)b 71.6 (65.7-77.5)ab 
 D+F 59.1 (55.0-63.2)a 82.2 (79.6-85.0)b 77.8 (67.1-88.5)b (n=5) 
DO2I (L m-2 min-1) D 563.5 (393.7-733.3)a 881.3 (740.1-1022)b 704.3 (562.1-846.5)ab 
 D+F 577.8 (418.3-737.4)a 727.3 (545.6-909.1)a 575 (555.9-594.1)a (n=4) 
CI (L m-2 min-1) D 4.4 (2.6-6.2) 5.4 (4.1-6.7) 4.5 (3.2-5.8) 
 D+F 4.5 (3.3-5.6) 5.5 (4.2-6.9) 4.5 (3.5-5.5) (n=5) 
CI (L kg-1 min-1)† D 0.057(0.035-0.079)  0.070(0.053-0.086) 0.058(0.042-0.074) 
 D+F 0.058(0.045-0.072)  0.072(0.055-0.09)  0.059(0.045-0.073) (n=5) 
SI (mL m-2) † D 130 (95-165) 142.5 (102.1-182.9) 120.2 (88.9-151.5) 
 D+F 133.6 (89.3-177.9) 143.8 (117.6-170.0) 126.9 (113.0-140.8) (n=5) 
UL FBF (mL m-2 min-1) D 157 (126.8-187.2)a 226.5 (178.8-274.2)a 187.0 (145.3-228.7)a 
 D+F 166.2 (130.0-202.7)a 289.5 (195.6-383.4)b 210.2 (131.5-288.9)ab (n=5) 
LL FBF (mL m-2 min-1) D 192.7 (167.2-218.1)a 257.5 (198.0-317.0)a 200.5 (168.6-232.4)a 
 D+F 229.5 (171.3-287.7)a 328.0 (239.8-416.2)b 238.4 (170.1-306.7)ab (n=5) 
HR- Heart rate, SAP – Systolic arterial pressure, MAP – Mean arterial pressure, DAP – 
Diastolic arterial pressure, DO2I – Oxygen delivery index, CI – Cardiac index, SI – 
Stroke volume index, UL FBF – Upper limb femoral arterial blood flow index, LL FBF - 




Table 3.2. Mean (95 % confidence interval) measured and calculated indices of oxygenation 
and ventilation recorded in isoflurane-anaesthetised horses. Unless otherwise stated, data is 
presented for 6 horses.T0, 60 minutes after induction of anaesthesia when MAP was 60 +/- 
5% mmHg for >15 minutes; T1, 30 minutes after onset of dobutamine administration after 
achieving a target of 80 (+/- 5%) mmHg; and T2, 15 minutes after stopping dobutamine (T2) 
in horses receiving dobutamine alone (D) or dobutamine and a 20 mL kg-1 bolus of 
Hartmann’s solution (D+F) intravenously. 
For variables with significant changes over time, means with the same superscript are not 
significantly different, while means with different superscript are significantly different; 
means at any time point with a * are different between treatments 
Parameter  Data collection point 
  T0 T1 T2 
Pa CO2 (mmHg) D 47.1 (42.6-51.6) 51.5 (45.9-57.1) 51.1 (46.6-55.5) 
 D+F 46.8 (41.7-51.9) 48.9 (42.7-55.1) 48.0 (40.0-57.5) (n=4) 
Pa CO2 (kPa) D 6.3 (5.7-6.9) 6.9 (6.1-7.6) 6.8 (6.2-7.3) 
 D+F 6.2 (5.56-6.9) 6.5 (5.7-7.3) 6.4 (5.3-7.7) (n=4) 
ET CO2 mmHg D 36.1 (30.0-42.4) 37.0 (34.1-40.0) 38.5 (32.5-44.5) 
 D+F 33.5 (30.0-37.7) 35.7 (30.4-41.0) 32.8 (25.8-40.0) (n=4) 
ET CO2 (kPa) D 4.8 (4-5.7) 4.9 (4.5-5.3) 5.1 (4.3-5.9) 
 D+F 4.5 (4-5) 4.8 (4.1-5.5) 4.4 (3.4-5.3) (n=4) 
PaO2 (mmHg) D 316 (210-421) 407 (283-521) 368 (270-466) 
 D+F  324 (213-436) 387 (273-501) 356 (108-604) (n=4) 
PaO2 (kPa) D 42.1 (28-56.1) 54.3 (37.7-69.5) 49 (36-62.1) 
 D+F 43.2 (28.4-58.1) 51.6 (36.4-66.8) 47.5 (14.4-80.5)(n=4) 
[Hb] (g dL-1) D 9.0 (8.2-9.9)a 11.5 (10.4-12.6)b* 11.2 (10.1-12.2)b* 
 D+F 8.9 (8.3-9.4)a 8.9 (8.4-9.4)a* 9.5 (9.1-9.9)a*(n=4) 
HCT (%) D 26.5 (24-29) 33.8 (30.5-37.1) 32.8 (29.6-36.1) 
 D+F 26.2 (24.5-27.9) 26.2 (24.8 – 27.6) 28.3 (27.5-29.1) (n=4) 
CaO2 (mLO2 L-1) D 130 (118-142.4)a 166.3 (148.4-184.2)b* 160.7 (143.8-177.5)b* 
 D+F 128.8 (122.6-134.9)a 131.5 (125.3-137.6)a* 139.3 (127.8-150.8)a* (n=4) 
PaCO2 – Arterial blood partial pressure of carbon dioxide, ETCO2 – End tidal carbon dioxide, PaO2 – Arterial 









This study compared the effects of dobutamine administration alone and in combination with 
a 20 mL/kg bwt Hartmann’s solution bolus on cardiovascular function in hypotensive 
isoflurane-anaesthetised horses premedicated with acepromazine. Our hypothesis was that a 
combination of dobutamine infusion and crystalloids would increase CI, DO2I and FBF, while 
dobutamine alone would not.  In addition, we proposed a lower rate of dobutamine infusion 
would be required to achieve target BP with dobutamine infusion and crystalloids than with 
dobutamine alone.  Our results did not completely reject this hypothesis.  Results supportive 
of the research hypothesis were the significant increase in FBF in both limbs during 
administration of dobutamine and fluids, while administration of dobutamine alone did not.  It 
was also hypothesized that administration of dobutamine and crystalloids would result in a 
persistent increase in DO2I, FBF and BP for 15 minutes after dobutamine infusion was 
stopped. The results of this study did not support this research hypothesis.   
4.1 Clinical relevance of study design 
This experimental study aimed to emulate the administration of dobutamine in a clinical 
setting, where dobutamine is administered to hypotensive horses and the rate of dobutamine 
administration is adjusted until an increase in MAP is achieved.  The end tidal isoflurane 
concentration was adjusted to achieve a target MAP within a specific time frame ensuring 
dobutamine was administered to hypotensive horses only.  While there was no significant 
difference in the end tidal isoflurane required to achieve target MAP of 60 mmHg (+/- 5 %) 
between treatments, it is important to note that the method used to measure the end-tidal agent 
concentration can be affected by expired methane, thus end tidal isoflurane percentage may 
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not be accurate (Dujardin et al 2005).  Despite this, the dose was adjusted to produce a 
standardized effect on MAP and thus the methodology should still be suitable to test the 
hypothesis.  
In our study the rate of dobutamine was adjusted to achieve a target increase in MAP of 80 
mmHg (+/- 5%). This contrasts with previous studies that administered dobutamine at a 
constant rate (Raisis et al 2000a, Young et al 1998, Dyson and Pascoe 1990) in normotensive 
horses (Raisis et al 2000a, Hinchcliff et al 1991).  The dose of dobutamine needed to achieve 
the required increase in MAP in this study did not differ significantly between treatments and 
was similar to previous studies [Mizuno et al 1994, de Vries et al 2009, Duronghongtorn et al 
2006, Hinchcliff et al 1991, Donaldson 1988, Lee et al 1998). 
4.2 Effect of dobutamine with and without fluids on DO2I 
The significant increase in DO2I observed during administration of dobutamine alone was not 
accompanied by a significant increase in CI.  This suggests that the increase in DO2I was due 
to the increase [Hb] and thus CaO2.  Increases in [Hb] associated with an increased PCV have 
been reported after dobutamine administration in halothane-anaesthetized horses (Raisis et al 
2000a, Lee et al 1998) and has been attributed to α-1 adrenoceptor mediated splenic 
contraction (Overgaard and Dzavik 2008). Interestingly the increase in [Hb] during 
dobutamine administration in the present study occurred despite the administration of 
acepromazine. Acepromazine has been reported to decrease PCV and thus [Hb] in conscious 
horses (Ballard et al 1982) and thus was expected to offset the effect of dobutamine. The 
failure to detect any change in DO2I during co-administration of fluids and dobutamine 
parallels the measurements of CI as well as the absence of change in CaO2 and [Hb].  The 
concurrent administration of dobutamine and fluids would likely result in haemodilution, 
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obscuring any increase in [Hb] and PCV mediated by dobutamine administration.  
Interestingly, although the increase in CaO2 and [Hb] during dobutamine administration alone 
resulted in a significant difference between treatments, there was no significant difference 
between treatments for DO2I.  This may be reflect the magnitude of variance in the face of a 
small sample size.  However, a sample of 300 horses would have been required to declare the 
difference in DO2I significant and thus even a moderate increase in sample size would not 
have changed the conclusion.  It is also worthy to note that the variability in measures of 
cardiac function observed in our study was comparable (deVries et al 2009) and lower 
(Mizuno et al 1994) than previous related equine anaesthetic studies.   
4.3 Effect of dobutamine with and without fluids on CI 
The failure of co-administration of fluids (20 mL kg-1 bwt Hartmann’s solution) and 
dobutamine to significantly increase CI in our study contrasts with finding in other species 
where co-administration of fluids and vasoactive agents was more effective at increasing Qt 
than vasoactive agents alone (Yoo et al 2007, Vane et al 2004).  This may reflect differences 
in study design such as a different physiological state of animals prior to treatment or the use 
of vasopressors rather than inotropes.  One study was performed in anaesthetised dogs 
suffering from haemorrhagic shock (Yoo et al 2007) and the other was performed in 
conscious normotensive sheep (Vane et al 2004).  It is also possible that lack of effect in our 
study was due to the redistribution of the fluids by the time Qt was recorded.  However, since 
[Hb] did not change and remained significantly lower during and after concurrent 
administration of dobutamine and fluids when compared to dobutamine alone, this 
explanation seems unlikely.  It is also possible in our study, that we failed to give a sufficient 
volume of fluids or possibly the cardiovascular effects of dobutamine and other sedative and 
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anaesthetic drugs administered predominated, thus preventing any effect associated with the 
volume of fluids administered in our study being detected.  
A possible but unlikely reason for lack of significant increase in CI within each horse during 
each treatment was interference with the measurement of Qt by administration of certain 
drugs, particularly at baseline.  Administration of xylazine has been observed to increase the 
measured voltage during performance of the lithium dilution technique resulting in an 
overestimation of Qt.  However this effect is reported to diminish 30 minutes after xylazine 
administration (Ambrisko and Moens 2014).  Another study in horses found good agreement 
between lithium dilution and LiDCO Qt measurements 60 minutes after induction of 
anaesthesia in horses that were premedicated with xylazine 0.8 mg kg-1 IV (Hopster et al 
2015).  Thus the impact of the xylazine premedication on LiDCO readings is considered 
unlikely in this study as data collection was started 60 minute after administration of xylazine. 
It is also worthy to note, that small but similar increases in PaCO2 from baseline were 
observed during both treatments despite maintaining constant PIP and RR. The reason for this 
could not be determined but may reflect changes in lung compliance and delivered tidal 
volume during the course of the study.  As, increases in PaCO2 are reported to stimulate the 
sympathetic nervous system (Brofman et al 1985), this would be expected to increase Qt and 
thus does not explain the lack of significant change in CI observed during either treatment. 
Thus the exact reason for the lack of change in CI during dobutamine administration remains 
unclear. It is possible that one or more of the sedative and anaesthetic agents used in this 
study altered the response to dobutamine administration, however studies specifically 




4.4 Effect of dobutamine with and without fluids on FBF 
Interestingly, FBF significantly increased in horses during concurrent administration of fluids 
and dobutamine.  An increase in FBF in the absence of increases in CI, has been observed in 
halothane-anaesthetized horses (Raisis et al 2000a) and suggests that the increase in FBF can 
be explained by considering Poiseuille’s Law.   
According to Poiseuille’s Law, flow within a blood vessel is, directly proportional to the 
perfusion pressure (pressure difference) within the vessel and the radius of the vessel, and 
inversely proportional to the viscosity of blood flowing through that vessel and length of the 
vessel. 
Volumetric flow = Π (pressure difference) (radius)4 
                               8 (viscosity) length 
As the targeted increase in BP observed between treatments in our study was similar, it is 
unlikely that a difference in perfusion pressure was responsible for the differences observed 
across treatments.  Similarly, as each horse was its own control, differences in vessel length 
between treatments should be minimal and unlikely to account for the differences observed 
across treatments. 
An increase in bilateral femoral vessel radius was observed with each treatment and could be 
the result dobutamine mediated beta-2 receptor stimulation (Shebuski et al 1987) or shear 
stress mediated vasodilation.  However the increase was minimal and similar between 
treatments and thus unlikely to account for the differences in FBF seen between treatments, 
although not tested statistically.  
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Viscosity is the internal property of fluid, which offers resistance to flow (Papaioannou and 
Stefanadis 2005).  Fluid viscosity is altered by temperature, packed cell volume and shear rate 
in horses. (Fedde and Erickson 1998). The statistically lower [Hb] observed in our study with 
the administration of dobutamine and fluids was the result of a lower HCT/PCV and would 
result in a lower blood viscosity (Fedde and Erickson 1998).  A lower blood viscosity would 
decrease the vascular resistance to femoral blood flow and may explain the increase in blood 
flow within the femoral arteries during concurrent administration of dobutamine and fluids 
when compared to the blood flow observed with dobutamine treatment alone.   
Reduction in blood viscosity has also been shown to improve microvascular flow in other 
species.  The impact of blood viscosity on peripheral tissue oxygenation has been shown 
experimentally. In a study involving halothane-anaesthetized dogs, a 20 % decrease in HCT 
and associated decrease in blood viscosity was produced by increasing haemodilution over 
time (Messmer et al 1973).  Haemodilution and a reduction in blood viscosity were associated 
with a significant increase in the mean partial pressure of oxygen in the tissues of organs 
studied.  Results of a number of similar studies prompted further research to determine the 
optimal PCV, at which overall oxygen delivery to the tissues via hemoglobin transport is 
maximized, in veterinary patients undergoing general anaesthesia (Gaehtgens et al 1979, Fan 
et al 1980).  However to date, the results of these studies have been variable and an optimal 
PCV has not yet been determined  
Based on these findings it is possible that co-administration of fluids and dobutamine may 
have a beneficial effect on muscle perfusion in anaesthetized horses, however further studies 




4.5 Conclusion  
4.5.1 General conclusion 
Administration of dobutamine alone resulted in a significant increase in DO2I and CaO2 due 
to the concurrent significant increase in [Hb], while dobutamine and fluids did not.  
Cardiac index did not significantly increase during either treatment. It is possible that no 
effect on CI was detected in this study with the administration of dobutamine and fluids due 
to a predominance of the cardiovascular effects of dobutamine and other sedative and 
anaesthetic drugs administered.  It may also reflect a failure to administer a large enough fluid 
bolus to effect a visible change in cardiovascular function or a failure to assess cardiovascular 
parameters with sufficient frequency. 
Dobutamine and fluids resulted in a significant increase in FBF in both limbs, due to a lower 
blood viscosity and thus reduced resistance to femoral blood flow, compared to treatment 
with dobutamine alone.  
The increase in FBF observed during the co-administration of dobutamine and fluids and the , 
suggests concurrent administration of dobutamine and fluids may have a beneficial effect on 
muscle perfusion relative to dobutamine administration alone in hypotensive isoflurane 
anaesthetised horses. The role of decreased PCV and blood viscosity on this finding warrant 
further investigation.  
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4.5.2 Future studies 
In future studies the use of a larger crystalloid bolus, lower fluid rate over a longer period of 
time or alternative fluid type in conjunction with the dobutamine infusion may effect greater 
cardiovascular changes than were seen in this study.   
The results of this study support further work in a variety of areas including fluid and 
vasoactive agent administration, blood viscosity and microvascular, regional and global 
oxygen delivery. 
Specifically studies could assess different fluid types, volumes and speed of administration on 
the cardiovascular function of hypotensive anaesthetized horses, to find the fluid and 
vasoactive agent combination which promotes optimal cardiovascular function. 
Studies could assess the impact of haemodilution on blood viscosity and correlate this with 
microvascular, regional and global oxygen delivery to obtain an optimal PCV for tissue 
oxygenation under general anaesthesia.  Studies could further assess whether vasoactive 
agents improve oxygen delivery. 
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Table 1. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine alone (treatment D) intravenously. 
 









Point	   Horse	  
Weight	  
(kg)	  
BSA	  	  	  	  	  	  	  	  	  
(m2)	  
Dose	  dobutamine	  	  
(	  µg	  	  kg-­‐1	  min-­‐1)	  
ET	  iso	  	  









CO-­‐AV	  	  	  	  	  
(L	  min-­‐1)	  
SV	  	  	  	  	  	  	  	  	  	  	  
(mL)	  
T0	   1	   578	   7.286	   0	   1.6	   1	   40.6	   85.2	   51.6	   62	   57.24	   1410	  
	  
2	   534	   6.91	   0	   1.6	   1	   28	   79.2	   50.4	   61.2	   23.68	   846	  
	  
3	   528	   6.859	   0	   2	   1	   34.5	   94	   51	   65	   23.17	   671	  
	  
4	   540	   6.963	   0	   1.5	   1	   33	   77.3	   50.3	   57.1	   25.38	   769	  
	  
5	   470	   6.347	   0	   1.4	   1	   31.5	   92	   49	   62	   26.02	   826	  
	  
6	   554	   7.083	   0	   1.5	   1	   32	   78	   50	   60	   29.29	   915	  
	   	   	   	   	   	  
	  
	   	   	   	   	   	  T1	   1	   578	   7.286	   0.5	   1.6	   1	   47.8	   95.8	   66	   77.8	   55.33	   1157	  
	  
2	   534	   6.911	   1	   1.6	   1	   31.2	   108	   61.6	   77.6	   36.95	   1184	  
	  
3	   528	   6.859	   1.5	   2	   1	   32	   116.4	   64.2	   80.6	   25.53	   798	  
	  
4	   540	   6.963	   1	   1.5	   1	   38.8	   110.5	   65.2	   79.6	   38.79	   1000	  
	  
5	   470	   6.347	   1	   1.4	   1	   26	   123	   59	   75	   30.46	   1172	  
	  
6	   554	   7.083	   1	   1.5	   1	   66	   97	   71.5	   81.5	   37.59	   570	  
	   	   	   	   	   	  
	  
	   	   	   	   	   	  T2	   1	   578	   7.286	   0	   1.6	   1	   40.6	   95	   64.4	   77	   46.11	   1136	  
	  
2	   534	   6.911	   0	   1.6	   1	   30.8	   83.6	   51.6	   64.8	   25.48	   827	  
	  
3	   528	   6.859	   0	   2	   1	   29.4	   93.8	   52.4	   65.6	   19.86	   675	  
	  
4	   540	   6.963	   0	   1.5	   1	   34	   95	   62.2	   75.4	   28.2	   829	  
	  
5	   470	   6.347	   0	   1.3	   1	   35.5	   96	   58	   70	   33.87	   954	  
	  
6	   554	   7.083	   0	   1.5	   1	   58	   94	   70	   77	   32	   552	  
BSA-­‐body	  surface	  area,	  ET	  iso-­‐end	  tidal	  isoflurane,	  FiO2	  –	  Fresh	  inspired	  oxygen,	  HR-­‐heart	  rate,	  SAP-­‐systolic	  arterial	  pressure,	  MAP-­‐mean	  arterial	  pressure,	  DAP-­‐diastolic	  
arterial	  pressure,	  CO-­‐AV	  -­‐	  cardiac	  output	  (average	  of	  two	  measurements),	  SV-­‐stroke	  volume	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Table 2. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine and a 10L bolus of Hartmann’s solution (treatment D+F) intravenously. 
Data	  
Point	   Horse	  
Weight	  	  




(µg	  kg-­‐1	  min-­‐1)	  
ET	  iso	  	  	  	  
(%)	   FiO2	  
HR	  	  	  	  	  
(bpm)	  








SV	  	  	  	  	  	  	  
(mL)	  
T0	   1	   566	   7.185	   0	   1.6	   1	   40	   80	   52.8	   61.2	   33.06	   826	  
	  
2	   536	   6.928	   0	   1.9	   1	   32	   89	   52.3	   66	   30.98	   968	  
	  
3	   487	   6.499	   0	   1.9	   1	   32	   85	   40	   55	   21.95	   686	  
	  
4	   509	   6.693	   0	   1.3	   1	   35	   83	   47.3	   58	   26.32	   752	  
	  
5	   464	   6.293	   0	   1.7	   1	   35.3	   84.4	   46.2	   57.2	   25.04	   709	  
	  
6	   562	   7.151	   0	   1.4	   1	   30	   77.2	   46.6	   57.4	   46.4	   1547	  
	   	   	   	   	   	  
	  
	   	   	   	   	   	  T1	   1	   566	   7.185	   0.25	   1.6	   1	   42	   107.6	   68	   84.6	   40.05	   953	  
	  
2	   536	   6.928	   0.5	   2	   1	   38	   108.4	   69.8	   85.6	   31.03	   817	  
	  
3	   487	   6.499	   1.5	   1.9	   1	   33	   121	   61.5	   80	   28.15	   853	  
	  
4	   509	   6.693	   1.5	   1.3	   1	   40	   118	   64	   82	   50.35	   1259	  
	  
5	   464	   6.293	   0.5	   1.7	   1	   34	   101.2	   65.6	   79	   29.28	   861	  
	  
6	   562	   7.151	   0.25	   1.5	   1	   42.8	   101.6	   69.8	   82.2	   47.74	   1115	  
	   	   	   	   	   	  
	  
	   	   	   	   	   	  T2	   1	   566	   7.185	   0	   	  	   	   41	   113	   83.5	   96	  
	   	  
	  
2	   536	   6.928	   0	   2	   1	   33	   100.4	   69.4	   82.6	   30.35	   920	  
	  
3	   487	   6.499	   0	   1.9	   1	   31	   99	   56	   72.5	   24.5	   790	  
	  
4	   509	   6.693	   0	   1.3	   1	   41	   90	   57	   71	   39.45	   962	  
	  
5	   464	   6.293	   0	   1.7	   1	   35	   88.2	   55	   68.4	   25.67	   733	  
	  
6	   562	   7.151	   0	   1.5	   1	   36	   92.8	   62.4	   76	   30.88	   858	  
BSA-­‐body	  surface	  area,	  ET	  iso-­‐end	  tidal	  isoflurane,	  FiO2	  –	  Fresh	  inspired	  oxygen,	  HR-­‐heart	  rate,	  SAP-­‐systolic	  arterial	  pressure,	  MAP-­‐mean	  arterial	  pressure,	  DAP-­‐





Table 3. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine alone (treatment D) intravenously. 
Data	  
Point	   Horse	  
Upper	  Limb	   Lower	  Limb	  
Dia	  AV	  	  
(cm)	  
TAV	  	  	  	  	  	  	  
(cm	  s-­‐1)	  
Flow	  	  	  	  	  	  	  	  
(mL	  min-­‐1)	  
UL	  FBF	  	  	  	  	  	  	  	  	  
(mL	  	  m-­‐2	  min-­‐1)	  
UL	  FBF	  	  	  	  	  	  	  	  	  
(mL	  kg-­‐1	  min-­‐1)	  
Dia	  AV	  	  	  	  
(cm)	  
TAV	  	  	  	  	  	  
(cm	  sec-­‐1)	  
Flow	  	  	  	  	  (mL	  
min-­‐1)	  
LL	  FBF	  	  	  	  	  	  	  	  	  
(mL	  m-­‐2	  min-­‐1)	  
LL	  FBF	  	  	  	  	  	  	  	  	  	  	  	  	  
(mL	  kg-­‐1	  min-­‐1)	  
T0	   1	   1.19	   18.3	   1228	   168.55	   2.125	   1.26	   19.7	   1481.64	   203.36	   2.563	  
	   2	   1.16	   12.95	   816	   118.07	   1.528	   1.21	   17.05	   1176.35	   170.21	   2.203	  
	   3	   1.14	   16.4	   1010	   147.25	   1.913	   1.18	   18.85	   1229.87	   179.3	   2.329	  
	   4	   1.18	   14.4	   950	   136.44	   1.759	   1.19	   17.2	   1154.23	   165.77	   2.137	  
	   5	   1.18	   19.2	   1253	   197.4	   2.666	   1.2	   20.9	   1418.24	   223.44	   3.018	  
	   6	   1.26	   16.5	   1241	   175.22	   2.24	   1.25	   20.7	   1524.16	   215.2	   2.751	  
	   	  
	   	   	  
	   	  
	   	   	  
	   	  
T1	   1	   1.3	   24	   1902	   261.06	   3.291	   1.31	   24	   1940.86	   266.39	   3.358	  
	   2	   1.23	   17.7	   1269	   183.62	   2.376	   1.24	   20.6	   1492.63	   215.97	   2.795	  
	   3	   1.15	   18.8	   1172	   170.86	   2.22	   1.19	   19.7	   1322	   192.73	   2.504	  
	   4	   1.25	   20.4	   1502	   215.72	   2.781	   1.22	   21.9	   1544.45	   221.81	   2.86	  
	   5	   1.22	   26.1	   1841	   290.05	   3.917	   1.3	   25.5	   2030.8	   319.95	   4.321	  
	   6	   1.36	   19.2	   1682	   237.48	   3.036	   1.36	   26.5	   2321.08	   327.71	   4.19	  
	   	  
	   	   	  
	   	  
	   	   	  
	   	  
T2	   1	   1.31	   22.4	   1811	   248.57	   3.133	   1.27	   24.1	   1831.75	   251.42	   3.169	  
	   2	   1.23	   15.1	   1077	   155.84	   2.017	   1.24	   16.75	   1207.15	   174.67	   2.261	  
	   3	   1.13	   16.3	   975	   142.14	   1.847	   1.19	   17	   1134.45	   165.39	   2.149	  
	   4	   1.22	   20.3	   1424	   204.51	   2.637	   1.21	   21.30	   1477.68	   212.22	   2.736	  
	   5	   1.11	   18.1	   1051	   165.58	   2.236	   1.16	   19.7	   1242.01	   195.68	   2.643	  
	   6	   1.36	   16.5	   1445	   204.02	   2.608	   1.36	   16.5	   1445.2	   204.05	   2.609	  
Dia	  Av	  –	  Average	  femoral	  arterial	  diameter,	  TAV	  –	  Time	  averaged	  mean	  velocity,	  Flow	  –	  Femoral	  arterial	  flow,	  
UL	  FBF	  –	  Lower	  limb	  femoral	  arterial	  blood	  flow	  index,	  LL	  FBF	  –	  Upper	  limb	  femoral	  arterial	  blood	  flow	  index	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Table 4. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine and a 10L bolus of Hartmann’s solution (treatment D+F) intravenously. 
Data	  	  
Point	   Horse	  








(mL	  	  m-­‐2	  min-­‐1)	  
UL	  FBF	  	  







LL	  FBF	  	  
(mL	  m-­‐2	  min-­‐1)	  
LL	  FBF	  
(mL	  kg-­‐1	  min-­‐1)	  
T0	   1	   1.28	   15.65	   1208	   168.14	   2.134	   1.28	   22.9	   1758.86	   244.81	   3.108	  
	   2	   1.2	   14.5	   984	   142.02	   1.836	   1.23	   16.5	   1182.73	   170.71	   2.207	  
	   3	   1.15	   11.5	   717	   110.32	   1.472	   1.13	   17.8	   1077.4	   165.77	   2.212	  
	   4	   1.28	   16.2	   1257	   187.79	   2.47	   1.22	   26.8	   1879.73	   280.82	   3.693	  
	   5	   1.25	   17.4	   1288	   204.67	   2.776	   1.24	   18.8	   1354.89	   215.3	   2.92	  
	   6	   1.38	   14.6	   1317	   184.18	   2.343	   1.36	   24.5	   2135.43	   298.63	   3.8	  
	   	  
	   	   	  
	   	   	  
	   	  
	   	  
T1	   1	   1.33	   27	   2251	   313.31	   3.977	   1.33	   28.9	   2397	   333.63	   4.235	  
	   2	   1.23	   21.1	   1504	   217.08	   2.806	   1.25	   23.3	   1715.6	   247.62	   3.201	  
	   3	   1.18	   17.8	   1175	   180.79	   2.413	   1.16	   23.8	   1500.49	   230.86	   3.081	  
	   4	   1.38	   31.3	   2823	   421.74	   5.546	   1.31	   37.1	   3015.54	   450.5	   5.924	  
	   5	   1.28	   20.8	   1598	   253.93	   3.444	   1.27	   26	   1965.8	   312.37	   4.237	  
	   6	   1.42	   26.5	   2506	   350.46	   4.459	   1.36	   32.2	   2806.56	   392.49	   4.994	  
	   	  
	   	   	  
	   	   	  
	   	  
	   	  
T2	   1	  
	   	   	  
	   	   	  
	   	  
	   	  
	   2	   1.25	   19.7	   1458	   210.44	   2.72	   1.25	   19.8	   1457.89	   210.42	   2.72	  
	   3	   1.17	   14.8	   949	   146.01	   1949	   1.16	   20.1	   1281.87	   197.23	   2.632	  
	   4	   1.34	   24.8	   2109	   315.07	   4.143	   1.24	   27.2	   1970.85	   294.43	   3.872	  
	   5	   1.29	   14.6	   1139	   180.99	   2.455	   1.25	   16.05	   1188.1	   188.79	   2.561	  
	   6	   1.37	   16.1	   1424	   199.14	   2.534	   1.39	   23.8	   2156.56	   301.59	   3.837	  
Dia	  Av	  –	  Average	  femoral	  arterial	  diameter,	  TAV	  –	  Time	  averaged	  mean	  velocity,	  Flow	  –	  Femoral	  arterial	  flow,	  
UL	  FBF	  –	  Upper	  limb	  femoral	  arterial	  blood	  flow	  index,	  LL	  FBF	  –	  Lower	  limb	  femoral	  arterial	  blood	  flow	  index	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Table 5. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine alone (treatment D) intravenously. 
Data	  Point	   Horse	   ETCO2	  (mmHg)	   ETCO2	  (kPa)	   PaCO2	  (mmHg)	   PaCO2	  (kPa)	   PaO2	  (mmHg)	   PaO2	  (kPa)	  
T0	   1	   35	   4.7	   52.8	   7	   246	   32.8	  
	   2	   44	   5.9	   44.5	   5.9	   392	   52.3	  
	   3	   35	   4.7	   46.8	   6.2	   392	   52.3	  
	   4	   32	   4.3	   45.1	   6	   230	   30.7	  
	   5	   33	   4.4	   41.7	   5.6	   433	   57.7	  
	   6	   30	   4	   51.6	   6.9	   202	   26.9	  
	   	   	   	   	   	   	   	  
T1	   1	   40	   5.3	   68.7	   9.2	   251	   33.5	  
	   2	   36	   4.8	   49.8	   6.6	   456	   60.8	  
	   3	   37	   4.9	   49.1	   6.5	   491	   65.5	  
	   4	   35	   4.7	   52.8	   7	   371	   49.5	  
	   5	   35	   4.7	   43.4	   5.8	   542	   72.3	  
	   6	   35	   4.7	   55.2	   7.4	   332	   44.3	  
	   	  
	   	   	   	   	   	  
T2	   1	   44	   5.9	   67.8	   9	   223	   29.7	  
	   2	   33	   4.4	   49.4	   6.6	   432	   57.6	  
	   3	   36	   4.8	   49.2	   6.6	   471	   62.8	  
	   4	   35	   4.7	   54.6	   7.3	   309	   41.2	  
	   5	   36	   4.8	   46.6	   6.2	   429	   57.2	  
	   6	   30	   4	   48.7	   6.5	   342	   45.6	  
ETCO2	  (mmHg)	  –	  End	  tidal	  carbon	  dioxide	  (millimetres	  of	  mercury),	  ETCO2	  (kPa)	  –	  End	  tidal	  carbon	  dioxide	  (kilopascals),	  PaCO2	  (mmHg)	  –
Arterial	  blood	  partial	  pressure	  of	  oxygen	  (millimetres	  of	  mercury),	  PaCO2	  (kPa)	  –	  Arterial	  blood	  partial	  pressure	  of	  carbon	  dioxide	  




Table 6. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine and a 10L bolus of Hartmann’s solution (treatment D+F) intravenously. 
Data	  
Point	   Horse	   ETCO2	  (mmHg)	   ETCO2	  (kPa)	   PaCO2	  (mmHg)	   PaCO2	  (kPa)	   PaO2	  (mmHg)	   PaO2	  (kPa)	  
T0	   1	   29	   3.9	   47.2	   6.3	   314	   41.9	  
	   2	   36	   4.8	   47.9	   6.4	   222	   29.6	  
	   3	   29	   3.9	   39.9	   5.3	   489	   65.2	  
	   4	   36	   4.8	   45	   6	   336	   44.8	  
	   5	   31	   4.1	   45.5	   6	   383	   51	  
	   6	   39	   5.2	   57	   7.6	   203	   27	  
	   	  
	   	   	   	   	   	  T1	   1	   31	   4.1	   48.2	   6.4	   408	   54.4	  
	   2	   41	   5.5	   56.1	   7.5	   266	   35.5	  
	   3	   31	   4.1	   41.2	   5.5	   554	   73.9	  
	   4	   42	   5.6	   49	   6.5	   446	   59.5	  
	   5	   32	   4.3	   43.7	   5.8	   373	   49.7	  
	   6	   37	   4.9	   55.7	   7.4	   276	   36.8	  
	   	  
	   	   	   	   	   	  T2	   1	   Woke	   Woke	   Woke	   Woke	   Woke	   Woke	  
	   2	   39	   5.2	   56.4	   7.5	   238	   31.7	  
	   3	   32	   4.3	   43	   5.7	   572	   76.3	  
	   4	   40	   5.3	  
	   	   	   	  	   5	   31	   4.1	   45.7	   6.1	   370	   49.3	  
	   6	   29	   3.9	   46.7	   6.2	   245	   32.7	  
ETCO2	  (mmHg)	  –	  End	  tidal	  carbon	  dioxide	  (millimetres	  of	  mercury),	  ETCO2	  (kPa)	  –	  End	  tidal	  carbon	  dioxide	  (kilopascals),	  PaCO2	  (mmHg)	  –
Arterial	  blood	  partial	  pressure	  of	  oxygen	  (millimetres	  of	  mercury),	  PaCO2	  (kPa)	  –	  Arterial	  blood	  partial	  pressure	  of	  carbon	  dioxide	  




Table 7. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine alone (treatment D) intravenously. 
Data	  








(L	  m-­‐2	  min-­‐1)	  
CI	  (BW)	  
(L	  kg-­‐1	  min-­‐1)	  
SI	  (BSA)	  	  
(mL	  m-­‐2)	  
SI	  (BW)	  	  
(mL	  kg-­‐1)	  
CaO2	  mL	  	  
(O2	  L
-­‐1)	  
DO2I	  (BSA)	  L	  
L	  m-­‐2	  min-­‐1	  
DO2I	  (BW)	  	  
L	  kg-­‐1	  min-­‐1	  
T0	   1	   7.8	   23	   100	   7.856	   0.099	   193.51	   2.439	   112.146	   881.02	   11.10	  
	   2	   9.9	   29	   100	   3.426	   0.044	   122.37	   1.584	   144.42	   494.78	   6.35	  
	   3	   9.2	   27	   100	   3.377	   0.044	   97.89	   1.272	   135.04	   456.03	   5.94	  
	   4	   8.8	   26	   100	   3.644	   0.047	   110.44	   1.424	   124.82	   454.84	   5.87	  
	   5	   8.5	   25	   100	   4.099	   0.055	   130.14	   1.758	   126.89	   520.12	   6.98	  
	   6	   9.9	   29	   100	   4.135	   0.053	   129.23	   1.652	   138.72	   573.61	   7.35	  
	   	  
	   	   	   	   	   	   	   	  
	   	  
T1	   1	   9.5	   28	   100	   7.594	   0.096	   158.86	   2.002	   134.83	   1023.90	   12.94	  
	   2	   12.6	   37	   100	   5.346	   0.069	   171.36	   2.218	   182.25	   974.31	   12.58	  
	   3	   11.9	   35	   100	   3.722	   0.048	   116.31	   1.511	   174.19	   648.34	   8.36	  
	   4	   11.9	   35	   100	   5.57	   0.072	   143.56	   1.851	   170.59	   950.19	   12.28	  
	   5	   11.9	   35	   100	   4.799	   0.065	   184.57	   2.493	   175.72	   843.28	   11.42	  
	   6	   11.2	   33	   100	   5.307	   0.068	   80.41	   1.028	   160.04	   849.33	   10.88	  
	   	  
	   	   	   	   	   	   	   	  
	   	  
T2	   1	   9.2	   27	   100	   6.329	   0.08	   155.88	   1.965	   129.97	   822.58	   10.40	  
	   2	   12.2	   36	   100	   3.686	   0.048	   119.68	   1.549	   176.44	   650.36	   8.47	  
	   3	   11.6	   34	   100	   2.895	   0.038	   98.46	   1.279	   169.57	   490.91	   6.44	  
	   4	   11.6	   34	   100	   4.049	   0.052	   119.1	   1.536	   164.71	   666.91	   8.56	  
	   5	   11.2	   33	   100	   5.336	   0.072	   150.31	   2.03	   162.95	   869.50	   11.73	  
	   6	   11.2	   33	   100	   4.519	   0.058	   77.91	   0.996	   160.34	   724.58	   9.30	  
Hb-­‐Haemoglobin,	  Hct-­‐Haematocrit,	  SaO2-­‐	  Arterial	  haemaglobin	  oxygen	  saturation,	  CI	  (BSA)	  -­‐	  Cardiac	  index	  (body	  surface	  area),	  CI	  (BW)	  -­‐	  Cardiac	  
index	  (body	  weight),	  SI	  (BSA)	  -­‐	  Stroke	  index	  (body	  surface	  area),	  SI	  (BW)	  –	  Stroke	  index	  (body	  weight),	  CaO2	  -­‐	  Arterial	  oxygen	  content,	  DO2I	  (BSA)	  -­‐	  
Oxygen	  delivery	  (body	  surface	  area),	  DO2I	  (BW)	  -­‐	  Oxygen	  delivery	  (body	  weight)	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Table 8. Data collected from horses anaesthetised with isoflurane 60 minutes after induction of anaesthesia when Map was 60 +/- 5% mmHg for >15 minutes 
(T0); at end of dobutamine administration after achieving a target MAP of 80 (+/- 5%) mmHg (T1) and 15 minutes after stopping dobutamine (T2) in horses 
receiving dobutamine and a 10L bolus of Hartmann’s solution (treatment D+F) intravenously. 
Data	  
Point	   Horse	  
Hb	  	  	  	  	  	  	  
(g	  dL-­‐1)	  
HCT	  
(%)	   SaO2	  (%)	  
CI	  (BSA)	  	  	  	  	  	  	  	  	  
(L	  BSA-­‐1	  min-­‐1)	  
CI	  (BW)	  	  	  	  	  	  	  	  	  	  





CaO2	  	  	  	  	  	  	  
(mL	  O2	  L
-­‐1)	  
DO2I	  	  	  	  	  	  	  	  	  	  	  
(L	  m-­‐2	  min-­‐1)	  
DO2I	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
(L	  kg-­‐1	  min-­‐1)	  
T0	   1	   8.5	   25	   100	   4.6	   0.058	   115.02	   1.46	   123.32	   567.27	   7.15	  
	   2	   9.5	   28	   100	   4.471	   0.058	   139.73	   1.806	   133.96	   598.94	   7.77	  
	   3	   8.8	   26	   100	   3.377	   0.045	   105.54	   1.408	   132.59	   447.76	   5.97	  
	   4	   8.2	   24	   100	   3.931	   0.052	   112.32	   1.477	   119.96	   471.56	   6.24	  
	   5	   8.8	   26	   100	   3.978	   0.054	   112.7	   1.528	   129.41	   514.79	   6.99	  
	   6	   9.5	   28	   100	   6.489	   0.083	   216.3	   2.752	   133.39	   865.57	   11.07	  
	   	  
	   	   	   	   	   	   	   	  
	   	  
T1	   1	   8.2	   24	   100	   5.574	   0.071	   132.71	   1.685	   122.12	   680.70	   8.67	  
	   2	   9.5	   28	   100	   4.479	   0.058	   117.86	   1.523	   135.28	   605.92	   7.85	  
	   3	   8.8	   26	   100	   4.331	   0.058	   131.25	   1.752	   134.54	   582.69	   7.80	  
	   4	   9.5	   26	   100	   7.522	   0.099	   188.05	   2.473	   140.68	   1058.19	   13.93	  
	   5	   9.2	   27	   100	   4.653	   0.063	   136.84	   1.856	   134.47	   625.69	   8.47	  
	   6	   8.8	   26	   100	   6.676	   0.085	   155.99	   1.985	   126.2	   842.51	   10.73	  
	   	  
	   	   	   	   	   	   	   	  
	   	  
T2	   1	  
	   	   	   	   	   	   	   	  
	   	  
	   2	   9.5	   28	   100	   4.381	   0.057	   132.74	   1.716	   134.44	   588.98	   7.66	  
	   3	   9.9	   29	   100	   3.77	   0.05	   121.6	   1.623	   149.82	   564.82	   7.49	  
	   4	   	  	  
	  
100	   5.894	   0.078	   143.75	   1.89	   	  	   	  	   	  	  
	   5	   9.5	   28	   100	   4.079	   0.055	   116.54	   1.581	   138.4	   564.53	   7.61	  
	   6	   9.5	   28	   100	   4.318	   0.055	   119.94	   1526	   134.65	   581.42	   7.41	  
Hb-­‐Haemoglobin,	  Hct-­‐Haematocrit,	  SaO2-­‐	  Arterial	  haemaglobin	  oxygen	  saturation,	  CI	  (BSA)	  -­‐	  Cardiac	  index	  (body	  surface	  area),	  CI	  (BW)	  -­‐	  
Cardiac	  index	  (body	  weight),	  SI	  (BSA)	  -­‐	  Stroke	  index	  (body	  surface	  area),	  SI	  (BW)	  –	  Stroke	  index	  (body	  weight),	  CaO2	  -­‐	  Arterial	  oxygen	  content,	  
DO2I	  (BSA)	  -­‐	  Oxygen	  delivery	  (body	  surface	  area),	  DO2I	  (BW)	  -­‐	  Oxygen	  delivery	  (body	  weight)	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